Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 2/2014

01-02-2014 | Case study

Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei

Authors: P. Berkovic, M.D., L. van de Voorde, M.D., G. De Meerleer, M.D., Ph.D., L. Delrue, M.D., Ph.D., B. Speleers, R.T.T., S. Van Belle, M.D., Ph.D., K. Vandecasteele, M.D., Ph.D.

Published in: Strahlentherapie und Onkologie | Issue 2/2014

Login to get access

Abstract

Background

Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by mucinous peritoneal disease arising from disseminated peritoneal adenomucinosis. Primary treatment involves a combination of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). There is no consensus on the proper treatment of recurrent PMP. In selected patients, repeated cytoreductive surgery with or without HIPEC might improve outcome. However, every repeated debulking procedure becomes less effective with increased morbidity.

Case report

We present a case of a patient with intestinal obstruction caused by recurrent pseudomyxoma peritonei. We treated the patient with whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT) to a total dose of 33 Gy, delivered in 22 daily fractions. The treatment was well tolerated and resulted in resolution of the obstruction for a period of 24 months.

Conclusion

To the best of our knowledge, we present the first case report showing the possibility of resolving intestinal obstruction with WAPRT in a patient with recurrent PMP. It is our opinion that WAPRT delivered by IMAT, in analogy with ovarian cancer, should be considered as a palliative treatment option in managing patients with recurrent PMP especially in case of obstruction.
Literature
1.
Ayhan A, Reed N, Gultekin M et al (2011) Textbook of gynaecologic oncology, 2nd edn. Hünes Publishing, Ankara
2.
Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456PubMedCrossRef
3.
De Meerleer G, Vandecasteele K, Ost P et al (2011) Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience. Int J Radiat Oncol Biol Phys 79:775–781CrossRef
4.
Dembo AJ (1992) Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys 22:835–845PubMedCrossRef
5.
Dowdy SC, Metzinger DS, Gebhart JB et al (2005) Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer. Gynecol Oncol 96:389–394PubMedCrossRef
6.
Duthoy W, De Gersem W, Vergote K et al (2003) Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. Int J Radiat Oncol Biol Phys 57:1019–1032PubMedCrossRef
7.
El Sayed S (1990) Pseudomyxoma peritonei treated by radiotherapy. Clin Oncol 2:120–122CrossRef
8.
9.
Gough DB, Donohue JH, Schutt AJ et al (1994) Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219:112–119PubMedCrossRef
10.
11.
Long RT, Spratt JS Jr, Dowling E (1969) Pseudomyxoma peritonei. New concepts in management with a report of seventeen patients. Am J Surg 117:162–169PubMedCrossRef
12.
Moran B, Baratti D, Yan TD et al (2008) Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 98:277–282PubMedCrossRef
13.
Nakakura EK (2012) Pseudomyxoma peritonei: more questions than answers. J Clin Oncol 30:2429–2430PubMedCrossRef
14.
Rochet N, Sterzing F, Jensen A et al (2008) Helical tomotherapy as a new treatment technique for whole abdominal irradiation. Strahlenther Onkol 184:145–149PubMedCrossRef
15.
Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85–91PubMedCrossRef
16.
Ronnett BM, Zahn CM, Kurman RJ et al (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 19:1390–1408PubMedCrossRef
17.
Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky Performance Status revisited: reliability, validity, and guidelines. J Clin Oncol 2:187–193PubMed
18.
Smeenk RM, Bruin SC, Van Velthuysen ML et al (2008) Pseudomyxoma peritonei. Curr Probl Surg 45:527–575PubMedCrossRef
19.
20.
Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69–76PubMedCrossRef
21.
Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181PubMedCrossRef
22.
Yan TD, Bijelic L, Sugarbaker PH (2007) Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol 14:2289–2299PubMedCrossRef
23.
Yoon WS, Yang DS, Lee JA et al (2012) Risk factors related to interfractional variation in whole pelvic irradiation for locally advanced pelvic malignancies. Strahlenther Onkol 188:395–401PubMedCrossRef
Metadata
Title
Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei
Authors
P. Berkovic, M.D.
L. van de Voorde, M.D.
G. De Meerleer, M.D., Ph.D.
L. Delrue, M.D., Ph.D.
B. Speleers, R.T.T.
S. Van Belle, M.D., Ph.D.
K. Vandecasteele, M.D., Ph.D.
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 2/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0470-7

Other articles of this Issue 2/2014

Strahlentherapie und Onkologie 2/2014 Go to the issue

Literatur kommentiert

Zusatz von Cetuximab zur primären Radiochemotherapie von Ösophaguskarzinomen verursacht schlechteres Gesamtüberleben

Original article

Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer

Original article

External-beam radiation therapy after surgical resection and intraoperative electron-beam radiation therapy for oligorecurrent gynecological cancer

Mitteilungen der Fachgesellschaften

Mitteilungen der Fachgesellschaften

Original article

The QUIRO Study (assurance of quality and innovation in radiooncology): methodology, instruments and practices

Letter to the editor

Effects of chemotherapy on the parotid and submandibular glands in head and neck cancer patients treated with chemoradiotherapy